About our Instructors:
Dennis L. Cooper, M.D.
Professor of Medicine (Hematology)
Yale Cancer CenterDennis Cooper, M.D., is a Professor of Internal Medicine(Hematology) at the Yale School of Medicine. Following graduation from RushMedical School, he completed his residency in Internal Medicine at Yale-NewHaven Hospital followed by a chief residency at the University of Pittsburgh. He returned to Yale for his fellowship training and then served as Fellowship Director and Clinical Director of the Hematopoietic Stem Cell Transplant Service. His clinical interests are recurrent lymphoma, multiple myeloma, and hematopoietic stem cell transplantation.Douglas Smith, M.D.
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterB. Douglas Smith is Associate Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, and is on the active staff of Johns Hopkins Hospital. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed an internship, residency, and chief residency at Strong Memorial Hospital in Rochester, New York. At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies.
Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them into biology-based treatment approaches for patients with AML, CML, and MDS. He has developed collaborations with several laboratory-based physician-scientists and has help to translate differentiation-based strategies, small molecule inhibitors of signal transduction pathways (including, FLT3 mutated AML, raf kinase, ras kinase, and bcr-abl), and immunomodulatory approaches. Many of these trials share the common theme on studying the impact of the treatment on the leukemic stem cell in hopes of limiting these cells’ roles in treatment failure.
Dr. Smith serves on the NCCN Guideline panels for both AML and CML and as associate editor for the journals Leukemia and The Journal of Clinical Oncology. In addition, he is a member of American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research.
Richard Stone, M.D.
Program Director, Adult Leukemia
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer InstituteDr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: firstname.lastname@example.org
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesReports & Market Researchbarnett educational servicesNews & AdvertisingKnowledge Foundation IT Trainingprofessional services
executive teamtestimonialschi timelinemailing listcareers